1. Home
  2. CFBK vs MOLN Comparison

CFBK vs MOLN Comparison

Compare CFBK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$27.80

Market Cap

184.4M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$3.93

Market Cap

158.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CFBK
MOLN
Founded
1892
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
184.4M
158.9M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
CFBK
MOLN
Price
$27.80
$3.93
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$29.00
$8.38
AVG Volume (30 Days)
41.7K
3.4K
Earning Date
05-05-2026
03-12-2026
Dividend Yield
1.30%
N/A
EPS Growth
30.58
N/A
EPS
2.69
N/A
Revenue
N/A
N/A
Revenue This Year
$32.28
N/A
Revenue Next Year
N/A
$318.52
P/E Ratio
$10.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.22
$3.36
52 Week High
$34.34
$5.36

Technical Indicators

Market Signals
Indicator
CFBK
MOLN
Relative Strength Index (RSI) 40.67 31.65
Support Level $23.49 $3.51
Resistance Level $29.95 $4.07
Average True Range (ATR) 0.69 0.26
MACD -0.05 -0.08
Stochastic Oscillator 33.75 16.67

Price Performance

Historical Comparison
CFBK
MOLN

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: